Nxera Pharma Co., Ltd.
Other OTCCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Christopher Cargill
- Full Time Employees
- 382
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- PMO Hanzomon Tokyo TY Japan 102-0083
- IPO Date
- Sep 4, 2013
- Website
- nxera.life
- Similar Companies
- Business
- Nxera Pharma Co., Ltd. (TSE: 4565) is a technology-driven biopharmaceutical company that discovers, develops, and commercializes specialty medicines targeting unmet needs in neurology, gastrointestinal and immunology, metabolic disorders, and rare diseases; it leverages its proprietary NxWave platform for structure-based drug design focused on G protein-coupled receptors (GPCRs) to advance a pipeline of over 30 programs, including in-house candidates such as PIVLAZ (clazosentan) for prevention of cerebral vasospasm after aneurysmal subarachnoid hemorrhage, QUVIVIQ (daridorexant) for insomnia, EP4 agonists and antagonists for inflammatory bowel disease and immuno-oncology, GPR52 agonists for schizophrenia, GPR35 agonists for GI disorders, and multiple agonists/antagonists targeting GLP-1, GIP, amylin, and apelin pathways for obesity-related diseases; the company also pursues late-stage development and commercialization of in-licensed assets in Japan and Asia-Pacific (excluding China), alongside partnering early clinical proof-of-concept programs globally while retaining regional rights. Founded in 1990 and headquartered in Tokyo, Japan, Nxera Pharma operates across Japan, the United Kingdom, Switzerland, South Korea, the United States, Germany, and Bermuda, with subsidiaries including Nxera Pharma UK Limited (formerly Heptares Therapeutics) and regional entities in Japan and Korea; it generates revenue primarily through alliances with global pharmaceutical companies and direct sales of marketed products. In recent developments, the company rebranded from Sosei Group in April 2024 to reflect its evolution into a next-generation biopharma leader following key acquisitions such as Heptares Therapeutics in 2015 and Idorsia Pharmaceuticals Japan and Korea in 2023, which included rights to PIVLAZ, daridorexant, and an option for lucerastat; additionally, in 2025 Nxera received a US$10 million milestone payment from AbbVie under their 2022 multi-target GPCR collaboration for neurological diseases, marking the second such payment after one in June 2024, with potential for up to US$1.2 billion in further milestones and royalties.
Nxera Joins OpenFold AI Research Consortium Alongside Leading Global Pharmaceutical and AI Companies to Accelerate AI-enabled Drug Discovery
Nxera's Vamorolone Granted Key Regulatory Designations Supporting Faster Access for Duchenne Muscular Dystrophy Patients in South Korea
Nxera's President & CEO to Participate in a ‘Fireside Chat' at the Jefferies New York Healthcare Conference 2026
Nxera Pharma Announces Progress of Out-Licensing of GPCR-targeted Program and Participation in Series A Financing
Nxera Files Patent Infringement Action in Relation to its miniG Platform Technology
Nxera Pharma to Receive US$10 Million Milestone Payment from AbbVie under Collaboration Targeting Neurological Diseases
Nxera Pharma Co., Ltd. (OTCMKTS:SOLTF) Short Interest Update
Nxera Pharma's QUVIVIQ® (daridorexant) 25mg and 50mg Receives Approval in Taiwan for the Treatment of Insomnia
Nxera Pharma’s Partner Neurocrine Biosciences Doses First Patient in Phase 2 Trial of NBI-1117570 for Adults with Schizophrenia
Nxera Pharma Achieves Second Development Milestone in Collaboration with Eli Lilly Targeting Metabolic Diseases
Nxera Pharma’s Partner Centessa Pharmaceuticals to be Acquired by Lilly
Nxera Pharma to Receive US$3 Million Milestone Payment from Centessa Pharmaceuticals
Nxera Pharma Submits Marketing Authorization Application for Daridorexant in South Korea
Nxera Pharma Co., Ltd. (SOLTF) Q4 2025 Earnings Call Transcript
Nxera Pharma Proposes Changes to its Board of Directors
Nxera Pharma Operational Highlights and Consolidated Results for the Fourth Quarter and Full Year 2025
Nxera Pharma to Receive $1.8 Million Milestone Payment from Centessa Pharmaceuticals
Nxera Pharma Licenses GPCR-targeted Program to Newly Founded Spin-out Company
Nxera Pharma Co., Ltd. (SOLTF) Presents at 44th Annual J.P.
Nxera Pharma to Receive US$3.6 Million in Milestone Payment Pursuant to Research Collaboration with Centessa